Product logins

Find logins to all Clarivate products below.


Location Location Location: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic Device Industry

Patients surgically treated for orthopedic indications have a unique set of characteristics when compared with other surgical patients; critically, surgical treatment for these patients is often elective. This differentiating factor is one of many contributing drivers to the noticeable changing site of service for some orthopedic procedures; many orthopedic procedures are moving away from the traditional hospital setting and towards ambulatory surgical centers. As a key stakeholder, medical device firms have to come to grips with this changing landscape and demonstrate the strategic willingness to capitalize on this trend. In spite of the presence of many significant obstacles, including but not limited to challenges to reimbursement in the ASC setting, medical device manufacturers looking to benefit from this site of service shift must adapt their existing portfolios, make an effort to understand the reimbursement and demographic landscape relevant to ASCs, and adjust their pricing and marketing strategies to target ASCs. In so doing, as ASCs assume a more pivotal role in orthopedic care over time, orthopedic medical device companies taking these steps can better ready themselves to effectively compete in the increasingly entrenched orthopedic device market.

Related Market Assessment Reports

Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Obesity – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity (US)
GLP-1 RA products have set new standards for weight-loss drugs and are driving the rapid growth of the obesity market. Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Zepbound…